Equities

Vimta Labs Ltd

VIMTALABS:NSI

Vimta Labs Ltd

Actions
Health CareMedical Equipment and Services
  • Price (INR)563.65
  • Today's Change-6.35 / -1.11%
  • Shares traded122.54k
  • 1 Year change+4.77%
  • Beta1.1138
Data delayed at least 15 minutes, as of Sep 20 2024 11:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vimta Labs Limited is engaged in the business of contract research and testing organization. The Company is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include Drug discovery, development, and drug life cycle management support services; Preclinical research and testing services for medical device companies; Contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; Clinical diagnostics services to patients, clinicians, and hospitals, and environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure.

  • Revenue in INR (TTM)3.17bn
  • Net income in INR410.91m
  • Incorporated1990
  • Employees1.43k
  • Location
    Vimta Labs LtdPlot No.141/2 & 142IDA, Phase-II, CherlapallyHYDERABAD 500051IndiaIND
  • Phone+91 4 027264141
  • Fax+91 4 027263657
  • Websitehttps://vimta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dimerix Ltd33.25m-973.10m12.06bn0.00--11.50--362.77-0.0373-0.03730.00130.03310.0234--0.0612---68.53-71.97-98.37-113.16-----2,926.42-8,332.83----0.0082--1,485.97100.27-23.71--17.99--
Pell Bio Med Technology Co Ltd47.12m-1.06bn12.13bn----3.41--257.50-8.02-8.020.34123.770.013210.434.23---29.90---34.86---113.22---2,262.16--7.19--0.0985--5.11---73.27------
Vimta Labs Ltd3.17bn410.91m12.63bn1.43k31.09--16.833.9918.3218.32141.14--------2,216,604.00--10.53--12.7776.4873.6512.9812.16--26.56--5.580.02238.40-14.8710.1335.880.00
Healios KK306.07m-3.16bn12.74bn64.00--6.69--41.61-68.16-68.166.5636.000.0321--1.618,156,250.00-33.11-23.55-49.17-28.5285.06---1,030.65-6,580.16---1.490.7469--34.44--26.04---22.00--
Wuhan YZY Biopharma Co Ltd0.00-2.17bn12.83bn114.00--21.92-----1.06-1.060.000.28150.00----0.00-83.99---230.17----------1.21-44.350.7078-------1.50------
Data as of Sep 20 2024. Currency figures normalised to Vimta Labs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

2.01%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 30 Jun 2023326.85k1.47%
Dimensional Fund Advisors LPas of 05 Sep 2024113.56k0.51%
American Century Investment Management, Inc.as of 05 Sep 20242.97k0.01%
Dimensional Fund Advisors Ltd.as of 30 Nov 20232.60k0.01%
DFA Australia Ltd.as of 31 Jul 2024535.000.00%
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2024102.000.00%
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.